1,700% increase in one year: Can this French biotech continue its growth?

A Spectacular Run Marred by Consolidation

The numbers are staggering: Abivax was trading around 7 euros a year ago. The French biotech company now boasts a 1,680% performance over the past twelve months, driven by an exceptional upward trajectory in the sector. However, recent dynamics tell a different story.

Over the past three months, the stock has declined by 5.73%, indicating a loss of momentum. While the performance over seven days remains positive (+2.93%), the price is now below its 20-day moving average (103.32 euros) and 50-day moving average (102.57 euros), reflecting a weakening short-term trend. The RSI, at 38, is nearing the oversold territory, confirming selling pressure in recent weeks. The technical support identified at 93.70 euros serves as a crucial level to watch, while resistance is at 112.40 euros. It's worth noting that the 200-day moving average, at 72.79 euros, remains significantly below the current price, highlighting the strength of the long-term trend despite the ongoing consolidation.

Annual Results in Ten Days: A Double-Edged Catalyst

For an investor, the question of timing is critically important. The stock is in a compression zone between its short-term moving averages and its technical support, within an environment of significant monthly volatility (13.92). The negative beta of -0.25 also indicates a decoupling from the market, which can serve as a diversification asset but also a source of unpredictability.

The major short-term event is the release of the 2025 annual results, scheduled for March 23. This event could act as a catalyst, either positively or negatively, warranting increased vigilance. A break above the resistance at 112.40 euros following this release would signal a resumption of upward momentum. Conversely, a drop below the support at 93.70 euros would open the risk of a more pronounced correction.

The current consolidation, after such an exceptional trajectory, is not abnormal from a technical perspective. It reflects a phase of digesting accumulated gains. However, the weakened RSI and positioning below the short-term averages call for caution for anyone considering entering before the financial report is released. The Paris market, stable during the session with the CAC 40 around 7,986 points, does not offer significant directional support this Friday.